KPIs - The New Medium-term Business Plan (2)

	TOP

	Financial Results for FYE March 2018 and New Medium-term Business Plan

	Agenda

	1. Overview of STEP UP 17

	2. The Meiji Group 2026 Vision

	3. The New Medium-term Business Plan Key Strategies Food: Expanding Yogurt, Chocolate, and Nutritional Products Food: Cultivate Future Growth Drivers Pharma: Maximize Product Value in Core Domains and Enhance Presence Pharma: Expand Sales of Generic Drugs and Accelerate Biosimilar Development to Drive Growth Food: Launch High Value-added Products, Invest Intensely in Overseas Business Pharma: Expand CMO/CDMO Business at Medreich Food: Continue Structural Reforms to Improve Productivity Food: Improve Profitability in Milk Business Pharma: Structural Reform and Platform Development to Grow Income from Overseas Agricultural Chemicals and Veterinary Drug Business KPIs - The New Medium-term Business Plan (1) KPIs - The New Medium-term Business Plan (2) Use of Cash Flows

	4. Outlook for the FYE March 2019

	Appendix: Financial data

	Appendix: Topics

	Back cover

Food segment
JPY 110 billion in operating income for FYE March 2021

• Sales growth for core and growth domain products will drive income

• Expand sales by investing in marketing

Pharmaceutical segment
JPY 15 billion in operating income

• Anticipating two NHI drug price revisions during 2020 Medium-Term Business Plan

• Offset by growing sales of brand-name drugs and generic drugs

• Secure income from agricultural chemicals and overseas business